Standard of Care Treatment Options

Choosing a treatment for severe aplastic anemia (SAA) is a highly individualized process. Because the disease is so rare, your care team will weigh several factors—including your age, the severity of your blood counts, and the availability of a donor—to determine which of the two primary treatment “paths” is right for you ^[1][2].

Note: Before and alongside definitive treatments, patients will receive supportive care, such as red-cell and platelet transfusions, and infection prophylaxis, to stabilize their condition.

Path 1: Immunosuppressive Therapy (IST)

The goal of IST is to quiet the overactive immune system, allowing your remaining stem cells to begin producing blood again ^[3]. For decades, the standard was a two-drug combination. However, recent research (specifically the RACE trial) has established a new “triple therapy” as a guideline-supported frontline option for selected patients with acquired severe disease who are not proceeding directly to transplant ^[3][4].

• Horse Antithymocyte Globulin (h-ATG): This is an intensive protein-based medicine given through an IV over several days in the hospital ^[5]. It works by depleting the T-cells that are attacking your bone marrow.
• Cyclosporine: This is an oral medication taken for many months, which is tapered slowly over many months or years depending on protocol, to keep the immune system from restarting its attack ^[6][4]. Tapering must always be supervised by your doctor.
• Eltrombopag: This is a newer addition to frontline therapy. It is a thrombopoietin receptor agonist—a drug that mimics a natural signal in the body to tell the bone marrow to produce more platelets and stem cells ^[3][7].

What the evidence says: The RACE trial found that adding eltrombopag to the standard ATG/cyclosporine regimen significantly improved results. Patients on the triple therapy saw an overall hematologic response rate of 68% at six months, compared to 41% for those on the two-drug regimen ^[3]. It also shortened the time it took for blood counts to start recovering ^[3].

Path 2: Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

An allogeneic transplant (HSCT) involves replacing your “broken” immune system and bone marrow with healthy stem cells from a donor ^[1]. This is generally considered potentially curative, as it replaces the failing marrow system ^[8].

• When it is preferred: HSCT is often the first-line choice for selected younger, fit patients who have a matched sibling donor ^[1][2].
• Why age matters: While there is no longer a rigid age cutoff, younger patients typically tolerate the intensive conditioning (chemotherapy given before the transplant) better and have a lower risk of complications. The decision relies on a shared framework regarding comorbidities ^[2][9].
• Alternative Donors: If a sibling donor isn’t available, doctors may look for a matched unrelated donor (MUD) or consider a haploidentical (half-match) donor. In experienced centers, alternative-donor transplants are sometimes considered upfront for selected patients ^[1][10].

Comparing the Two Paths

The decision often comes down to balancing the risk of immediate complications against the risk of the disease returning later.

Potential Harms and Side Effects

Every treatment for SAA carries significant risks that require close monitoring by a specialist team.

IST Side Effects:

• Infusion Reactions: Horse ATG can cause fever, chills, and “serum sickness” (joint pain and rash) during or shortly after the infusion ^[5].
• Kidney & Blood Pressure: Cyclosporine can be hard on the kidneys (nephrotoxicity) and often causes high blood pressure ^[6].
• Liver Function: Eltrombopag is associated with hepatotoxicity (liver irritation). Many patients may see an increase in liver enzymes, requiring dose adjustments or temporary pauses ^[7][13].

Transplant Complications:

• Graft-versus-Host Disease (GVHD): This happens when the donor’s immune cells attack your body’s tissues (like skin, liver, or gut) ^[12][14].
• Graft Failure: In a percentage of cases, the donor cells may fail to “take” or grow in the recipient’s marrow ^[15].
• Infections: Because the immune system is deeply suppressed during the process, severe infections are a major risk and the leading cause of transplant-related complications ^[12][16].

If frontline treatment fails, second-line options include additional immunosuppression, alternative-donor transplants, or clinical trials. Your medical team will use specialized blood tests and frequent monitoring to catch and manage side effects early.